MIKSHIRA MOSELY: Open Payments
NPI 1780160606 · NEW ORLEANS, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,216 in 21 payments from 17 companies in 2025. Trend: 2023 $1,442 · 2024 $1,639 · 2025 $2,216
Food & beverage: $2,216
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 2 | $250 |
| Dexcom, Inc. | 1 | $163 |
| Janssen Pharmaceuticals, Inc | 1 | $150 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $140 |
| Janssen Biotech, Inc. | 1 | $137 |
| Exact Sciences Corporation | 2 | $132 |
| Amgen Inc. | 1 | $127 |
| GENZYME CORPORATION | 1 | $125 |
| AstraZeneca Pharmaceuticals LP | 1 | $125 |
| Novo Nordisk Inc | 1 | $123 |
Products named: FANAPT, DEXCOM G7 GSS (161), SPRAVATO, Kerendia, KRYSTEXXA, DUPIXENT, Wegovy, REZDIFFRA.
Industry payments across LA — which companies pay providers there.
